Company / Free Cash Flow
Moderna Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$2.1B
FY2025
5-year range
-$4.1B / $2.0B
FY2021-FY2025
Trend
+49.1%
vs FY2024
Sector context
#194 of 194
Health Care
What the data says
Among 194 Health Care companies, Moderna is in the bottom 0% for free cash flow. Free Cash Flow returned to growth in FY2025 after 2 years of decline, reaching -$2.1B.
Based on SEC 10-K filings.
-$2.1B in FY2025.
Improved from -$3.8B to -$2.1B over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 0% in Health CareTop 100% of 194This company -$2.1B Sector average $470.6M
▼
-538.8% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 49.1% year-over-year.
- Ranks #194 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2022.
- Lowest free cash flow in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 1.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.1B | +49.1% |
| FY2024 | -$4.1B | -6.0% |
| FY2023 | -$3.8B | -295.3% |
| FY2022 | $2.0B | +499.0% |
| FY2021 | -$491.0M | -125.1% |
| FY2020 | $2.0B | +499.0% |
| FY2019 | -$491.0M | -12.5% |
| FY2018 | -$436.6M | -12.0% |
| FY2017 | -$389.9M | -1260.7% |
| FY2016 | $33.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026